Genmab: Darzalex drug sales keep on rising

(CercleFinance.com) - Danish biotech company Genmab saw its shares rise slightly on Tuesday after saying that the quarterly sales of the Darzalex blood cancer drug were now approaching the 1 billion dollar threshold.


Sales of the treatment for patients with multiple myeloma, as reported by US partner Johnson & Johnson, totalled 937 million dollars in the first quarter of 2020, the firm said.

That compared with global net sales of 629 million dollars in the first quarter of 2019.

For the record, Genmab receives royalties on the global net sales of Darzalex under an exclusive worldwide license that was signed with Johnson & Johnson's Janssen.

Genmab shares are currently trading at 1,475.5 Danish kronor, a rise of 0.7%. They are however down over 7% year-to-date.

Copyright (c) 2020 CercleFinance.com. All rights reserved.